Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 28  |  Issue : 3  |  Page : 757-764

Effect of the antirheumatic drug leflunomide (Avara) on the lungs of adult male albino rats and the possible protective effect of N-acetylcysteine: histological and immunohistochemical study

Department of Histology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Correspondence Address:
Shaimaa M Abdel-Fattah Hasn
MSc, El-Harm, Giza 32511
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-2098.167898

Rights and Permissions

Objective The present study was conducted to throw light on the histological effects of the antirheumatic drug leflunomide (Avara) on the lungs of adult male albino rats, and to clarify the possible protective effect of N-acetylcysteine. Background Leflunomide (Avara) is an immunomodulating agent and disease-modifying antirheumatic drug with anti-inflammatory and immunosuppressive activity. N-acetylcysteine belongs to a class of drugs called antioxidants which may reduce the amount of damage caused by inflammation or active damage of the lungs. Materials and methods A total of 60 adult male albino rats were used in the present study. They were divided into four groups. Group I: The control group composed of 20 rats. Group II: The N-acetylcysteine-treated group composed of 10 rats received N-acetylcysteine in a daily oral dose of 200 mg/kg body weight. Group III: The leflunomide-treated group composed of 20 rats receiving leflunomide on a daily oral dose of 10 mg/kg body weight. Then, half the animals were killed 4 weeks after the treatment (subgroup IIIa), and the other half were left without treatment for another 2 weeks and served as the recovery group (subgroup IIIb). Group IV: The protected group composed of 10 rats receiving combined treatment of both leflunomide and N-acetylcysteine in the same previous doses and route of administration for 4 weeks. At the end of the study, animals were killed and specimens from the lungs were processed for both L/M, E/M, and immunohistochemical study (using caspase-3 immunostaining). Morphometric study for the number of pneumocyte type II was counted, and the thicknesses of the interalveolar septa were done and statically analyzed. Results The results of this study revealed that leflunomide treatment caused considerable histological, immunohistochemical, and ultrastructural changes in the lungs. Concomitant administration of N-acetylcysteine with leflunomide resulted in remarkable improvement, whereas arrest of treatment for 2 weeks revealed mild improvement. Conclusion N -acetylcysteine is proven to have a protective effect on the lungs against hazardous effects induced by leflunomide treatment. Therefore, strict follow-up and coadministration of N-acetylcysteine are highly recommended for those patients who use leflunomide.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded116    
    Comments [Add]    

Recommend this journal